Reglagene is delighted to add Sharon Ayd, PhD, MBA to its Board of Directors. In Dr. Ayd’s 30-year career, she has gained experience commercializing pharmaceuticals from discovery to clinical evaluation, expanded core businesses, and transformed pharmaceutical business operations. Her career began as a research scientist for Baxter International. She went on to serve in a variety of executive positions at companies including Apotex Inc., Hospira (now Pfizer), Fresenius-Kabi, Transcend Therapeutics, Advanced Life Sciences, and Pinnacle Biologics. Dr. Ayd is an industry expert in regulatory strategy and pharmaceutical operations. She has led the regulatory affairs activity for many due diligence projects, resulting in product licensing, mergers and acquisitions, and divestitures. Under her leadership, ~100 drug application approvals (original and supplements) have been obtained. Dr. Ayd holds an MBA from Lewis University and a PhD from the University of Illinois at Chicago in Biopharmaceutical Sciences, and she is an alumnus of Women In Bio’s inaugural class in its Boardroom Ready program, a foundational resource to prepare executive women for service on corporate boards.
Dr. Sharon Ayd Joins Reglagene Board of Directors
Updated: Feb 27